China’s CoronaVac safe for use in children: study
The Hindu
Higher dose induced neutralising antibody responses in trials of 3-17 year-olds
A higher dose of the Chinese vaccine CoronaVac was “well tolerated and safe, and induced neutralising antibody responses in children and adolescents aged 3-17 years”, a study in the recent edition of the peer-reviewed journal Lancet Infectious Diseases has stated. The seroconversion rates of neutralising antibodies in children and adolescents with two different doses were over 96% after a double-dose vaccination, the paper reported. The double-blind randomised, controlled, phase 1/2 clinical trial of CoronaVac (inactivated SARS-CoV-2), in healthy children and adolescents aged 3-17 years was conducted at the Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China).More Related News

NPCIL is to blame for storage of radioactive waste on site of Kudankulam nuclear power plant: Appavu
Tamil Nadu Speaker Appavu criticizes NPCIL for unsafe nuclear waste storage at Kudankulam, urging better solutions for public safety.












